Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation

Hepatology

Volumn 26, Issue 2, 1997, Pages 500-504

  Bizollon, Thierry ^a   Palazzo, Ugo ^c   Ducerf, Christian ^b   Chevallier, Miehele ^d   Elliorr, Michael ^e   Baulieux, Jacques ^b   Pouyet, Miehel ^c   Trepo, Christian ^a  

^a HÔTEL DIEU   (France)

^b CROIX ROUSSE HOSPITAL   (France)

^c Hospital Vincenzo Cervello   (Spain)

^d INSTITUT PASTEUR   (France)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CYCLOSPORIN A; ERYTHROPOIETIN; HEMOGLOBIN; METHYLPREDNISOLONE; OKT 3; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; TACROLIMUS; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT REJECTION; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER FAILURE; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENT INFECTION; REOPERATION; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS GENOME;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; RIBAVIRIN; RNA, VIRAL;

EID: 0030795196     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510260236     Document Type: Article

References (27)

1. Hôpf U, Müller B, Kuther D, Stemerowicz R, Lobeck H, Ludtke-Handjery A, Walter E, et al. Long term follow-up of post-transfusion and sporadic chronic hepatitis non A non B and frequency of circulating antibodies to hepatitis C virus. J Hepatol 1990;10:69-76.
2. Feray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, Udea M, Bismuth H. The course of hepatitis C infection after liver transplantation. HEPATOLOGY 1994;20:1137-1143.
3. Shah G, Demetris AJ, Gavaler JS, Lewis JH, Todo S, Starzl TE, Van Thiel DH. Incidence, prevalence, and clinical course of hepatitis C following liver transplantation. Gastroenterology 1992;103:323-324.
4. Chazouilleres O, Kim M, Combs C, Ferell L, Bacchetti P, Roberts J, Ascher NL. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994;106:994-999.
5. Feray C, Gigou M, Samuel D, Okamoto H, Reynes M, Mishiro S, Bismuth H, et al. Influence of genotype on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995;108:1089-1097.
6. Lau JYN, Davis G, Kniffer J, Quin KP, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-1504.
7. Simmonds P. Variability of hepatitis C virus. HEPATOLOGY 1995;21:570-583.
8. Peters M. Mechanisms of action of Interferon. Semin Liver Dis 1989;9:235-239.
9. Patterson JL, Fernandez-Loisson R. Molecular mechanism of action of ribavirin. Rev Infect Dis 1990;12:1139-1146.
10. DiBisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, Axiotis CA. A pilot study of ribavirin therapy for chronic hepatitis C. HEPATOLOGY 1992;16:649-654.
11. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991;337:1058-1061.
12. Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavirin and Interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993;105:507-512.
13. Brillanti S, Garson J, Mauro F, Whitby K, Masci C, Migioli M, Barbara L. A pilot study of combination therapy with ribavirin plus Interferon alpha for interferon alpha-resistant chronic hepatitis C. Gastroenterology 1994;107:812-817.
14. Scvarrcz R, Yun ZB, Sönnerborg A, Weiland O. Combined treatment with interferon alpha 2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995;46:43-47.
15. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymlomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
16. Lerat H, Berby F, Trabaud MA, Vidalin O, Major M, Trepo C, Inchaupse G. Specific detection on hepatitis C virus minus strand RNA in hematopoîtic cells. J Clin Invest 1996;9:845-851.
17. Wright HI, Gavaler JS, Van Thiel DH. Preliminary experience with α-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992;53:121-124.
18. Wright TL, Combs C, Kim M, Ferell L, Bachetti P, Ascher N, Roberts J. Interferon alpha therapy for hepatitis C virus infection following liver transplantation. HEPATOLOGY 1994;20:773-779.
19. Feray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, Reynes M, et al. An open trial of IFN alpha recombinant for hepatitis C after liver transplantation. HEPATOLOGY 1995;22:1084-1089.
20. Vargas V, Charco R, Castells L, Esteban R, Margarit C. Alpha-interferon for acute hepatitis in liver transplant patients. Transplant Proc 1995;27:1222-1223.
21. Gane EJ, Tibbs CJ, Ramage JK, Portmann EC, Williams R. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int 1995;8:61-64.
22. Hayden FG, Schlepushskin AN, Pushkarshava NL. Combined interferon-alpha 2, rimantadine hydrochloride and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother 1984;25:53-57.
23. Garson JA, Brillanti S, Ring C, Perini P, Miglioli M, Barbara L. Hepatitis C viraemia rebound after "successful" interferon therapy in patients with chronic non-A non-B hepatitis. J Med Virol 1992;37:210-214.
24. Kakumu S, Yoshika K, Tanaka K, Higashi Y, Kurokawa S, Hirofuji H, Kusakabe A. Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C. J Med Virol 1993;41:65-70.
25. Housset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients [Letter]. N Engl J Med 1994;330:1161.
26. Heagy W, Crumpacker C, Lopez PA, Finberg RW. Inhibition of immune functions by antiviral drugs. J Clin Invest 1991;87:1916-1924.
27. Jolley W, Sharma B, Chami R, Ng C, Bullington R. Long-term skin alograft survival by combined therapy with suboptimal dose of cyclosporin and ribavirin. Transplant Proc 1988;20:703-706.